전체메뉴

Journal of Pharmacopuncture

Article Search

JoP

Articles

Split Viewer
Review Article

Related articles in JoP

More Related Articles

Article

Review Article

J Pharmacopuncture 2020; 23(2): 54-61

Published online June 30, 2020 https://doi.org/10.3831/KPI.2020.23.009

Copyright © The Korean Pharmacopuncture Institute.

Current and Future molecular mechanism in Inflammation and Arthritis

Vikash Sharma1, Raj Kumar Tiwari1, Shiv Shankar Shukla1, and Ravindra Kumar Pandey1,*

Columbia Institute of Pharmacy, Raipur, C.G., India

Correspondence to:*Corresponding Author Ravindra Kumar Pandey. Columbia Institute of Pharmacy, Raipur, C.G., India., Tel: +91-982-6222-9321, Email: rajphama239@gmail.com

Received: January 24, 2020; Revised: February 4, 2020; Accepted: May 28, 2020

Abstract

Inflammation is an immune response of the human body but excessive inflammation is taken as a major factor in the development of many diseases including autoimmune disorders, cancer and nerve disorders etc. In this regards the need is to suppress the inflammatory response. Suppression of extra or imperfect inflammatory response is not a big deal provided there is an exact knowledge of particular target in the body. Recent advancements in Pharmacological aspect made the therapy with improved outcomes in number of patients. Anticytokine therapy might be one of the important and novel approaches for inflammation and Arthritis. This can be achieved only when we go through the pathophysiology of expression and identification of mediators. Let’s take an example of cytokine like interleukins (IL), chemokines, interferons (INF), tumor necrosis factors (TNF-α), growth factors, and colony stimulating factors) release pathway which is a major signalling protein in inflammatory response. In the present study we have reviewed the recent pharmacological therapeutic advancement, inflammatory mediators, receptors, and major signalling pathways. Such information will not only provide the idea about the mechanism of action of Pharmaceuticals and molecular targets but also it provides a new aspect for drug designing and new corrective approaches in existing clinical medicines. This study will be a source of good information for the researchers working in the area of drug designing and molecular Pharmacology especially in anti-inflammatory and anti arthritic medicines for target based therapy.

Keywords: inflammation, arthritis, cytokines, receptors, transcription factor

1. Introduction

1.1.1. Conventional or Traditional Synthetic DMARDs

Prevention of RA patient from the deformity and narrowing of joints can be achieved by using early diagnosis and treatment with DMARDs (Table 1). The prominent drugs modifying the disease condition from synthetic origin includes the analog of folic acid (Methotrexate), Pyrimidine synthesis inhibitor (Leflunomide) and Immunosuppressant (Sulfasalazine) [5].

Methotreaxate is a potent drug in modification of RA which is used in combination with other drugs. These drugs act on critical pathways involved in the progression of the disease. For example, Methotrexate initiates the release of adenosine and inhibit IL-1 IL-6 and IL-8 production. It also suppresses the cell-mediated immunity. Another drug Leflunomide is involved in the inhibition of proliferation.

1.1.2. Novel DMARDs or Target based therapy

1.1.2.1. Biologics

The mechanism of action of biological DMARDs (Table 2) is very much selective as they act by interfering with the production of cytokines, signal transduction for initiation of T cells thereby reducing the number of B cells. Biological DMARDs include TNF-α inhibitor (Infliximab), T cell and B cell-targeted therapy (Abatacept, Rituximab respectively) and cytokines targeted therapy (Tocilizumab) [6].

2. Molecular Pharmacology in Rheumatoid Arthritis

2.1. Cytokines

Cytokines are the major secreted and signalling proteins as a response against inflammation and the immune system. Cytokines bind to their receptors present over the membrane of the target cell, which initiates the signal transduction cascade resulting in altered gene expression in the target cell [7]. Cytokines include lymphokine, monokine, chemokine, and interleukin. Generally, cytokines show three types of actions. Cytokine can either bind to receptors on the membrane of the same cell (autocrine), or nearby cells (paracrine) and cells in the distal part of the human body. Cytokine binds with the receptor of the target cells generally activate the receptors and secretion of other cytokines. Cytokines are either pro-inflammatory or anti-inflammatory cytokines [8]. Pro-inflammatory mediators include IL-1, IL-6, transforming growth factor β (TGFβ), interferon γ (IFNγ) and Tumor necrosis factor α (TNFα), other cytokines include IL-4, IL-12, IL-10 [9].

Cytokines have diverse physiological roles which are inclusive of the development of cell-mediated and humoral immunity, inflammatory reactions, regulation of cell proliferation, wound healing. Activities of some most common cytokines have been summarized in Table 1 [10].

2.2.1. Nuclear factor NF-κB

There is a fundamental role of transcription factors in maintaining the expression of pro-inflammatory mediators in the progress of inflammation. These factors include mainly NF-κB, STAT1/STAT3. NF-κB expresses many complexes of members of the Rel (Reticuloendotheliosis) protein family [11]. Mainly this protein consists of two subunits p50 and p65 commonly referred to NF-κB/Rel complex. Initially, this remains in an inactive state in the cytoplasm of resting cells in an association of inhibitory IκB family (composed of two kinase subunits, IKBα and IKBβ) [12]. Activation of this protein is achieved by pro-inflammatory catalyst as cytokines, Lipopolysaccharide (LPS) by proteasomal degradation. Following the activation, the next step is the displacement of attachment of NF-κB to the promoter region of genes, results in activation of pro-inflammatory mediators, such as COX-2 and iNOS, etc [13]. NF-κB signaling causes the degradation of IkB results in the migration of NF-κB inside the nucleus where it serves as transcription factor. Finally, this contributes to the inflammatory responses in the cell. This was the first identified transcription factor in B cell having a significant role in inflammatory responses and other cellular responses as apoptosis. NF-κB is also supposed to have a significant role play in diseases such as arthritis, carcinoma, asthma, etc [14].

2.2.2. STATs

STATs transcription factors are also of immense importance in inflammation and many other immunological responses. STATs are responsible for sequential signaling initiated by cytokines; IL-6 family, epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) [15]. Activation of STATs initiated via cytokine receptor during phosphorylation of tyrosine kinase, JAK family. JAK-STAT pathway is involved in response to several cytokines and their response is also different as well. Initially, binding of cytokines to these receptors induces the dimerization of these cytokine receptors followed by attachment of a tyrosine kinase unit (JAK to associate) and thus, phosphorylation of receptor dimer takes place. JAK represents a group of protein molecule in which each protein has specificity for a unique receptor [16]. STATs are similarly a group of transcription factors, subject to phosphorylation by JAK. This phosphorylation of STAT stabilizes the Src homology 2 (SH2) domains by intercommunication of phosphotyrosine and SH2. After that, there is dimerization of STAT, reaching to nucleus and thus results in activation of a gene responsible for inflammatory modulators and other proteins regulating cell proliferation [17].

Currently, seven members of STATs family were identified, among them only five (STAT1-4 STAT6), execute as transcription factors. STAT1 and STAT2 were identified as mediators of IFN signaling. STAT2 involved in IFN type I (IFN-α, β) signaling, whereas STAT1 mediates signaling of both type I as well as type II IFN (IFN-ϒ). These two types of IFN are responsible for the inflammatory response in viral infection and bacterial defense. STAT 3 mediates IL-6 and IL-10. STAT 4 and STAT 6 have a significant involvement in acquired immune responses. Activation of STAT 4 depends on IL-12 and STAT 6 on IL-4, IL-13. STAT 4 play a major role in the development of autoimmune disorders whereas STAT6 is involved in allergic inflammatory reactions [18].

2.2.3. Toll like Receptors

Toll genes were first identified in the1980s and the first toll like receptor (TLR) was identified in 1996 [19]. There are approximately 13 TLRs and out of them, 11 are present in the human body. TLR functions as a microbial signature and are referred to as pathogen-associated molecular patterns (PAMPs). The molecules produced by damaged cells, are referred to as damage-associated molecules patterns (DAMPs) [20]. The initial activation is done by some specific encoded pattern-recognition receptors (PRRs) provide by the innate immune response. PRRs activate the signaling pathways which further initiates the innate immune response through the synthesis of cytokines and many other mediators. TLRs are expressed in inborn immune cells like macrophages. TLRs are grouped into two families according to their position across the cell; cell surface (Cell surface TLRs include TLR1, TLR2, TLR4-6, and TLR10) TLRs and intracellular TLRs (the endosome and include TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, and TLR13) [21-22].

3. Pathways in Inflammatory Signaling

3.1. Nuclear Factor-κB pathway

In the inactive stage, NF-κB complexes are attached with IκB kinase-α (IKKα), IκB kinase-β (IKKβ) and IKKγ/NEMO in the cytoplasm. This complex is activated by attachment of ligands as cytokine, growth factors or damaged microbial cells to the receptors present on the cell surface. The activated IKK complex causes phosphorylation of IκB. Further, there is proteasomal degradation of Phosphorylated IκB and causes the NF-κB activation, which reaches in the nucleus where serves as a transcription factor for the expression of specific target genes (Fig. 1) [23].

3.2. Mitogen-Activated Protein Kinase (MAPK) cascade

Ras is a product of proto-oncogene, works similar to G-protein. It transmits the signals through (GDP/GTP) SH2 domain protein Grb, where phosphorylation occurs by tyrosine receptor kinase. This causes Ras activation which results in the activation of Raf. In the next step, there is phosphorylation of both Ras and Raf. At last, there is the phosphorylation of various transcription factors by MAP kinase, interfere in transcription in the nucleus [24]. (Fig. 2)

3.3. JAK-STAT signaling pathway

Binding of cytokines to the receptors induces dimerization of these receptors and causes the phosphorylation of JAKs and STATs. Activation of STAT causes dimerization. These dimers serve as a transcription factor and causes gene transcription in the nucleus [25-26] (Fig. 3)

3.4. Phosphatidylinositol-3-Kinase (PI3K)/Akt signaling pathway

PI3K/Akt Pathway is one of the most important pathways which play a pivotal role in modulating cellular growth, proliferation, metabolism, and angiogenesis. Akt is a serine/threonine kinase consists of a kinase domain and a pleckstrin homology, initially identified as proto-oncogene. Binding of ligand to the receptor causes activation of PIP3 results in further signaling. Activation of PIP3 further activates Akt and PKB. Akt induces activation of nuclear factor NF-κB which has a significant role in inflammation [27].

3.5.1. Cyclo-oxygenase (COX)

COX is essentially found in two forms COX-1and COX-2. The metabolism of Arachidonic acid produces Prostaglandin H2 (PGH2), and formation of many other isomeric forms of prostanoids in different region of the body which depends on the cell type and degree of cellular activation [35] as PGD2, PGE2, PGF2α, thromboxane A2 (TXA2), PGI2 are found in vascular system, smooth muscle, platelets, and gastric mucosa respectively. PGE2 further activates PGE2 receptor which ultimately demonstrates the signs of inflammation and pain. PGE2 and TXA2 are found to be more significant in inflammatory reactions [36]. PGE2 produces its effect by another pathway; MAPK/ERK [37].

3.5.2. Lipo-oxygenase (LOX)

This pathway is mainly responsible for the production of leukotrienes and lipoxins. One significant role of this pathway is respiratory tract inflammation by enhancing bronchial constriction. Leukotrienes are produced by leukocyte like LTC4 production as a response to inflammation and cell injury. Similar to TXA2, it is a strong vasoconstrictor and acts via the Gq-protein pathway [38]. Leukotrienes and prostaglandins may also promote edema by making the vascular endothelium more "leaky" [39-40].

4. Conclusion

Inflammation plays an essential role in the progression and development of number of ailments as mentioned in the study. This review largely focuses on the inflammatory mediators, their role, release pathways and physiological significance. In this review, we have tried to summarize these mediators as molecular targets in the therapy of inflammation and designing of novel medicines. Now-a-days, new drug designing approaches have trended for targeted drug delivery system. As Arachidonic acid pathway is the specific target for the most prominent anti-inflammatory agents viz. Non-steroidal Anti-inflammatory drugs (NSAIDs). NSAIDs affect the arachidonic acid pathway and provide only symptomatic relief in case of arthritis and inflammation. Likewise, there are several other signaling molecules and transcription factors that have been summarized in the study may prove significant for relieving and targeting approach in the treatment of inflammation and Arthritis. This study might also be helpful in determination of possible method of such existing drugs whose mechanism is still unknown, in case of Ayurvedic and herbal medicines for the development of new drugs. This study possibly can be a breakthrough in herbal drug research for inflammatory ailments. Thus, to conclude that if a drug is showing anti-inflammatory action, it might be inhibiting one or many of the above mentioned targets. This study therefore provides the potential molecular aspect to young researchers working in drug development for inflammation and arthritis.

CONFLICTS OF INTEREST

Conflict of Iinterest

The authors have no conflict of interest.

Fig 1.

Figure 1.

Nuclear Factor-κB pathway. The nuclear factor-kappa (NF-_B) level differently regulates cartilage homeostasis. Upon ligand binding to the receptor present on the cell surface, the activated IKK causes phosphorylation of IκB which further results in NF-κB activation which translocate to the nucleus where serves as a transcription factor and bind to DNA to induce NF-κB target gene transcription which further results in various cellular responses like Apoptosis, Inflammation, Proliferation and Hypertrophy in chondrocytes. NF- κB induces catabolic gene expression through NF-_B response elements located in the promoters of the MMP1, MMP9, MMP13 and ADAMTS5 genes.

Journal of Pharmacopuncture 2020; 23: 54-61https://doi.org/10.3831/KPI.2020.23.009

Fig 2.

Figure 2.

Mitogen-Activated Protein Kinase (MAPK) cascade. This pathway plays a crucial role n the progression of Rheumatoid arthritis. MAPK pathway (right) are activated by the pro-inflammatory cytokines TNF-α and IL-1. MAPK cascade initiated by binding of ligands such as growth factors mitogens, cytokines and stress signals. MAPK cascade after phosphorylation of its components serves as transcription factor and binds to the DNA for genes coding for various cytokines including TNF-α and IL-1, other inflammatory molecules, such as prostaglandins (PGs), and proteases, such as the matrix metalloproteinases (MMPs). ERK1/2 controls PGE2 and MMP-1 production which contributes to the inflammation, angiogenesis, recruitment of cells from both innate and adaptive arms of the immune system, cartilage damage and bone erosion.

Journal of Pharmacopuncture 2020; 23: 54-61https://doi.org/10.3831/KPI.2020.23.009

Fig 3.

Figure 3.

JAK-STAT signaling pathway. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Upon ligand binding, Jak associated with cytokine receptors undergo transphosphorylation and mediate phosphorylation of specific tyrosine residues on the cytokine receptor. Binding of cytokines to the receptors induces dimerization of these receptors and causes the phosphorylation of JAKs and STATs. Activation of STAT causes dimerization. These dimers serve as a transcription factor and causes transcription of Matrix Metallopeptidase 13(MMP-13). The JAK/STAT signal transduction pathway is utilized by many cytokines and growth factors that regulate gene expression and cellular activation, proliferation, and differentiation.

Journal of Pharmacopuncture 2020; 23: 54-61https://doi.org/10.3831/KPI.2020.23.009

Fig 4.

Figure 4.

Arachidonic Acid Pathway. This Pathway involves the release of inflammatory mediators as Prostaglandins, thromboxanes, and leukotrienes as depicted in the figure. Phospholipase A2 activation initiates this pathway results in formation of Arachidonic Acid from the cell membrane. Then Arachidonic acid is metabolized into different mediators by some enzymatic reactions in presence of cyclooxygenase enzyme (COX) and Lipoxygenase (LOX).

Journal of Pharmacopuncture 2020; 23: 54-61https://doi.org/10.3831/KPI.2020.23.009

Table 1 . Drugs used for arthritis. Conventional Disease Modifying Anti-Rheumatic Drugs.

Conventional DMARDsMechanism of Action
MethotrexateFolic acid antagonist and Increase Adenosine release
SulfasalazineInhibition of Inflammatory mediators by Arachidonic AcidInhibition
HydroxychloroquineIncreases lysosomal pH in antigen-presenting cells, Blockade of Toll like receptor signaling
LeflunomideInhibition of dihydroorotate dehydrogenase (DHODH), an enzyme having role in pyrimidine synthesis

Table 2 . Drugs used for arthritis. Conventional Disease Modifying Anti-Rheumatic Drugs (DMARDs).

Biologics DMARDsMechanism of Action
InfliximabPrevent Binding of TNF-α to its receptor
EtanerceptPrevent Binding of TNF-α and TNF-β to its receptor
AdalimumabPrevent Binding of TNF-α to its receptor
AbataceptInhibition of T-lymphocytes, preventing cell mediated immune response
TocilizumabIL-6 Inhibition
TofacitinibInhibits Janus kinase (JAK) 1 and JAK3

References

  1. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. In-flammatory Responses and Inflammation-Associated Diseases in Organs. Oncotarget 2018;9:7204-7218.
    Pubmed KoreaMed CrossRef
  2. Korniluk A, Koper O, Kemona H, Dymicka-Piekar- ska D. From inflammation to cancer. Ir J Med Sci 2017;186:57-62.
    Pubmed KoreaMed CrossRef
  3. Gavrilă BI, Ciofu C, Stoica V. Biomarkers in Rheuma-toid Arthritis, what is new?. J Med Life 2016;9:144-148.
    Pubmed
  4. Burmester GR, Pope JE. Novel Treatment Strategies in Rheumatoid Arthritis. Lancet 2017;389:2338-2348.
    Pubmed CrossRef
  5. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheu-matoid Arthritis: Pathological Mechanisms and Mod-ern Pharmacologic Therapies. Bone Res 2018;6:1-14.
    Pubmed KoreaMed CrossRef
  6. Brown PM, Pratt AG, Isaacs JD. Mechanism of Action of Methotrexate in Rheumatoid Arthritis, and the Search for Biomarkers. Nat Rev Rheumatol 2016;12:731-742.
    Pubmed CrossRef
  7. Tasneem S, Liu B, Li B, Choudhary MI, Wang W. Mo-lecular Pharmacology of Inflammation: Medicinal Plants as Anti-Inflammatory Agents. Pharmacol Res 2019;139:126-140.
    Pubmed CrossRef
  8. Zhang JM, An J. Cytokines, Inflammation and Pain. Int Anesthesiol Clin 2007;45:27-37.
    Pubmed KoreaMed CrossRef
  9. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cy-tokines and Chemokines: At the Crossroads of Cell Sig-nalling and Inflammatory Disease. Biochim Biophys Acta 2014;1843:2563-2582.
    Pubmed CrossRef
  10. Kindt TJ, Goldsby RA, Osborne BA. Kuby Immunology. 6th ed. New York: Freeman press, 2007.
  11. Hammaker D, Sweeney S, Firestein G. Signal transduc-tion networks in rheumatoid arthritis. Ann Rheum Dis 2003;62:ii86-ii89.
    Pubmed KoreaMed CrossRef
  12. Seetharaman R, Mora AL, Nabozny G, Boothby M, Chen J. Essential Role of T Cell NF-kappa B Activation in Col-lagen-Induced Arthritis. J Immunol 1999;163:1577-83.
    Pubmed
  13. Wu Y, Antony S, Meitzler JL, Doroshow JH. Molecular mechanisms underlying chronic inflammation-associ-ated cancers. Cancer Lett 2014;345:164-173.
    Pubmed KoreaMed CrossRef
  14. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, et al. Mal (MyD88-adapter-like) is Required for Toll-like receptor-4 Signal Transduction. Nature 2001;413:78-83.
    Pubmed CrossRef
  15. Kaplan MH. STAT signaling in inflammation. JAK-STAT 2013;2:1-3.
    Pubmed KoreaMed CrossRef
  16. Yu H, Pardoll D, Jove R. STATs in Cancer Inflammation and Immunity: A Leading Role for STAT3. Nat Rev Can-cer 2009;9:798-809.
    Pubmed KoreaMed CrossRef
  17. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117:1281-1283.
    Pubmed CrossRef
  18. Seif F, Khosmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The Role of JAK-STAT Signaling Pathway and Its Regulators in the Fate of T Helper Cells. Cell Commun Signal 2017;15:23.
    Pubmed KoreaMed CrossRef
  19. Kawasaki T, Kawai T. Toll-Like Receptor Signaling Path-ways. Front Immunol 2014;5:1-8.
    Pubmed KoreaMed CrossRef
  20. Takeda K, Akira S. Toll-like Receptors. Curr Protoc Im-munol 2015;109:14.12.1-14.12.10.
    Pubmed CrossRef
  21. Takeda K, Kaisho T, Akira S. Toll-like Receptors. Annu Rev Immunol 2003;21:335-76.
    Pubmed CrossRef
  22. Kaisho T, Akira S. Toll-like Receptor Function and Sign-aling. J Allergy Clin Immunol 2006;117:979-87.
    Pubmed CrossRef
  23. Liu T, Zhang L, Joo D, Sun SC. NF-κB Signaling in Inflam-mation. Signal Transduct Target Ther 2017;2:17023.
    Pubmed KoreaMed CrossRef
  24. Soares-Silva M, Diniz FF, Gomes GN, Bahia D. The Mi-togen-Activated Protein Kinase (MAPK) Pathway: Role in Immune Evasion by Trypanosomatids. Front Micro-biol 2016;7:1-9.
    Pubmed KoreaMed CrossRef
  25. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117:1281-1283.
    Pubmed CrossRef
  26. Harrison DA. The JAK/STAT Pathway. Cold Spring Harb Perspect Biol 2012;4:a011205.
    Pubmed KoreaMed CrossRef
  27. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the Phosphoinositide 3-kinase Pathway in Cancer. Nat Rev Drug Discov 2009;8:627-44.
    Pubmed KoreaMed CrossRef
  28. Samuelsson B. Arachidonic Acid Metabolism: Role in Inflammation. Z Rheumatol 1991;50:3-6.
    Pubmed
  29. Yang G, Chen L. An Update of Microsomal Prosta-glandin E Synthase-1 and PGE2 Receptors in Cardio-vascular Health and Diseases. Oxid Med Cell Longev 2016;2016:5249086.
    Pubmed KoreaMed CrossRef
  30. Tallima H, Ridi RE. Arachidonic Acid: Physiological Roles and Potential Health Benefits -A Review. J Adv Res 2017;11:33-41.
    Pubmed KoreaMed CrossRef
  31. Hanna VS, Hafez EAA. Synopsis of arachidonic acid metabolism: A review. J Adv Res 2018;11:23-32.
    Pubmed KoreaMed CrossRef
  32. Poorani R, Bhatt AN, Dwarakanath BS, Das UN. COX-2, Aspirin and Metabolism of Arachidonic, Eicosapen-taenoic and Docosahexaenoic Acids and Their Physi-ological and Clinical Significance. Eur J Pharmacol 2016;15:116-132.
    Pubmed CrossRef
  33. Khanapure SP, Garvey DS, Janero DR, Letts LG. Eicos-anoids in Inflammation: Biosynthesis, Pharmacolo-gy, and Therapeutic Frontiers. Curr Top Med Chem 2007;7:311-40.
    Pubmed CrossRef
  34. Pannunzio A, Coluccia M. Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature. Pharmaceuticals (Basel) 2018;11:101.
    Pubmed KoreaMed CrossRef
  35. Dennis EA, Norris PC. Eicosanoid Storm in Infection and Inflammation. Nat Rev Immunol 2015;15:511-23.
    Pubmed KoreaMed CrossRef
  36. Ricciotti E, FitzGerald GA. Prostaglandins and Inflam-mation. Arterioscler Thromb Vasc Biol 2011;31:986-1000.
    Pubmed KoreaMed CrossRef
  37. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural, Cellular, and Molecular Biology. Annu Rev Biochem 2000;69:145-82.
    Pubmed CrossRef
  38. Requelme MA, Burra S, Kar R, Lampe P, Jiang JX. Mito-gen-activated Protein Kinase (MAPK) Activated by Pros-taglandin E2Phosphorylates Connexin 43 and Closes Osteocytic Hemichannels in Response to Continuous Flow Shear Stress. J Biol Chem 2015;290:28321-8.
    Pubmed KoreaMed CrossRef
  39. Paul CN, Dennis EA. A Lipidomic Perspective on In-flammatory Macrophage Eicosanoid Signaling. Adv Biol Regul 2014;54:99-110.
    Pubmed KoreaMed CrossRef
  40. Sirois P, Borgeat P. Pharmacology of the Leukotrienes. J Pharmacol 1984;15:53-68.